Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 15;13(2):e12249.
doi: 10.1002/pul2.12249. eCollection 2023 Apr.

Clinical features do not identify risk of progression from isolated postcapillary pulmonary hypertension to combined pre- and postcapillary pulmonary hypertension

Affiliations

Clinical features do not identify risk of progression from isolated postcapillary pulmonary hypertension to combined pre- and postcapillary pulmonary hypertension

Gautam Babu et al. Pulm Circ. .

Abstract

Pulmonary hypertension is a common sequelae of left heart failure and may present as isolated postcapillary pulmonary hypertension (Ipc-PH) or combined pre- and postcapillary pulmonary hypertension (Cpc-PH). Clinical features associated with progression from Ipc-PH to Cpc-PH have not yet been described. We extracted clinical data from patients who underwent right heart catheterizations (RHC) on two separate occasions. Ipc-PH was defined as mean pulmonary pressure >20 mmHg, pulmonary capillary wedge pressure >15 mmHg, and pulmonary vascular resistance (PVR) < 3 WU. Progression to Cpc-PH required an increase in PVR to ≥3 WU. We performed a retrospective cohort study with repeated assessments comparing subjects that progressed to Cpc-PH to subjects that remained with Ipc-PH. Of 153 patients with Ipc-PH at baseline who underwent a repeat RHC after a median of 0.7 years (IQR 0.2, 2.1), 33% (50/153) had developed Cpc-PH. In univariate analysis comparing the two groups at baseline, body mass index (BMI) and right atrial pressure were lower, while the prevalence of moderate or worse mitral regurgitation (MR) was higher among those who progressed. In age- and sex-adjusted multivariable analysis, only BMI (OR 0.94, 95% CI 0.90-0.99, p = 0.017, C = 0.655) and moderate or worse MR (OR 3.00, 95% CI 1.37-6.60, p = 0.006, C = 0.654) predicted progression, but with poor discriminatory power. This study suggests that clinical features alone cannot distinguish patients at risk for development of Cpc-PH and support the need for molecular and genetic studies to identify biomarkers of progression.

Keywords: biomarker; left heart disease; pulmonary circulation; vascular remodeling.

PubMed Disclaimer

Conflict of interest statement

Anna Hemnes serves as a consultant for United Therapeutics, Janssen, GossamerBio, and Merck. She holds stock in Tenax Therapeutics. The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representing the initial data set and subsequent criteria used to create the two comparison groups. Cpc‐PH, combined pre‐ and postcapillary pulmonary hypertension; Ipc‐PH, isolated postcapillary pulmonary hypertension; PH, pulmonary hypertension; PH‐LHD, pulmonary hypertension due to left heart disease; RHC, right heart catheterization.
Figure 2
Figure 2
Multivariable regression analysis to identify characteristics associated with progression to Cpc‐PH. Data reflect comorbidities and values at the time of repeat RHC reported as age‐ and sex‐adjusted odds ratio (95% confidence interval) with respective p value and C‐statistic. BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; Cpc‐PH, combined pre‐ and postcapillary pulmonary hypertension; DPG, diastolic pressure gradient; EF, ejection fraction; HDL, high‐density lipoproteins; LDL, low‐density lipoproteins; OSA, obstructive sleep apnea; PVR, pulmonary vascular resistance; RAP, mean right atrial pressure; RHC, right heart catheterization; TG‐HDL, triglyceride to HDL ratio.

References

    1. Fang JC, DeMarco T, Givertz MM, Borlaug BA, Lewis GD, Rame JE, Gomberg‐Maitland M, Murali S, Frantz RP, McGlothlin D, Horn EM, Benza RL. World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2012;31(9):913–33. - PubMed
    1. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913. - PMC - PubMed
    1. Gerges M, Gerges C, Pistritto AM, Lang MB, Trip P, Jakowitsch J, Binder T, Lang IM. Pulmonary hypertension in heart failure. epidemiology, right ventricular function, and survival. Am J Respir Crit Care Med. 2015;192(10):1234–46. - PubMed
    1. Assad TR, Hemnes AR, Larkin EK, Glazer AM, Xu M, Wells QS, Farber‐Eger EH, Sheng Q, Shyr Y, Harrell FE, Newman JH, Brittain EL. Clinical and biological insights into combined post‐ and pre‐capillary pulmonary hypertension. JACC. 2016;68(23):2525–36. - PMC - PubMed
    1. Miller WL, Grill DE, Borlaug BA. Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction. JACC Heart Fail. 2013;1(4):290–9. - PubMed